Piramal Pharma Share Price

Piramal Pharma Ltd

Piramal Pharma Limited (PPL) was incorporated as a public limited company on March 4, 2020, and subsequently registered with the Registrar of Companies (RoC). The company has made remarkable strides since its inception and has established a solid foundation in the pharmaceutical industry. It offers a comprehensive portfolio of differentiated products and services, which include an integrated Contract Development and Manufacturing Organization (CDMO) business, Contract Healthcare Group (CHG) business, and the India Consumer Healthcare (ICH) business. These services are supported by robust manufacturing capabilities, spanning 17 global facilities, and an extensive distribution network covering more than 100 countries.

Business Divisions and Key Offerings

Piramal Pharma has established itself as a prominent player in the pharmaceutical sector, with a diverse range of business units catering to various aspects of the industry. Its integrated CDMO business offers services across the entire lifecycle of a pharmaceutical molecule, from drug discovery and development to the manufacturing of active pharmaceutical ingredients (APIs) and drug products, including formulations. This service is crucial for pharmaceutical companies seeking to develop new drugs, and Piramal Pharma’s expertise in both drug substances and drug products has positioned it as a trusted partner in the global pharma ecosystem.

Furthermore, Piramal Pharma’s CHG business encompasses a range of products that cater to the consumer healthcare market in India. With well-established and widely recognized brands such as Saridon, Supradyn, Lacto Calamine, Littles, Tetmosol, iPill, and Polycrol, the company has made significant inroads into the self-care space. These brands have gained strong customer loyalty and have contributed to the company’s growing reputation in the Indian market. The company’s ICH business focuses on selling over-the-counter products in India, addressing the growing demand for easily accessible healthcare solutions.

Strategic Partnerships and Joint Ventures

One of the key strategic moves by Piramal Pharma was its joint venture with Allergan (now part of AbbVie), which is a leading name in ophthalmology. This partnership has significantly bolstered Piramal Pharma’s standing in the Indian formulations market. Piramal Pharma holds a 49% stake in Allergan India Private Limited, making it an influential player in the ophthalmic segment in India. This joint venture has allowed Piramal Pharma to access Allergan's extensive global expertise in ophthalmology, strengthening its position in both the Indian and international markets.

In addition to its joint venture with Allergan, Piramal Pharma also has a minority investment of 33.33% in Yapan Bio, a company specializing in biologics and vaccine development. This partnership allows Piramal Pharma to tap into the rapidly expanding biologics market, which is one of the most promising areas in modern pharmaceutical development. The company’s ability to leverage these partnerships gives it access to cutting-edge technologies and expertise that significantly enhance its service offerings.

Global Presence and Manufacturing Capabilities

Piramal Pharma’s global reach is a key factor in its success. With manufacturing facilities located across India, the United States, the United Kingdom, and Canada, the company has established a significant presence in both developed and emerging markets. The company’s 15 manufacturing facilities are strategically located to cater to its diverse customer base, ranging from large global pharmaceutical companies and biotech firms to hospitals and institutions. The global distribution network spanning over 100 countries further amplifies Piramal Pharma's reach, allowing it to offer its products and services to a wide range of clients worldwide.

In addition to its global manufacturing capabilities, Piramal Pharma has differentiated itself by offering specialized services in high-growth areas, such as highly potent APIs, antibody drug conjugates, sterile injectables, and hormonal oral solid dosage forms. These specialized capabilities enable the company to serve niche markets that require unique and complex pharmaceutical solutions. The company’s focus on biologics and vaccines is also positioning it as a significant player in the future of healthcare, as these areas are expected to witness considerable growth.

Acquisitions and Investments for Growth

Piramal Pharma’s growth strategy has been bolstered by strategic acquisitions and investments that have expanded its capabilities and market presence. In June 2020, the company acquired the pharmaceutical business from its parent company, Piramal Enterprises Limited (PEL). This acquisition allowed Piramal Pharma to strengthen its operations and expand its portfolio of products and services. Additionally, in October 2020, the company received growth equity investment from The Carlyle Group, a global investment firm. This investment enabled Piramal Pharma to further accelerate its expansion plans and solidify its position in the global pharmaceutical market.

Further enhancing its capabilities, Piramal Pharma acquired Convergence Chemicals Private Limited (CCPL) in 2020. This acquisition provided the company with expanded expertise in drug development and manufacturing, particularly in the area of chemical and pharmaceutical products. Piramal Pharma also acquired Hemmo Pharmaceuticals Private Limited (HPPL) in 2021, enabling the company to enhance its expertise in the development and manufacturing of peptide APIs.

Demerger and Listing on Stock Exchanges

In 2021, Piramal Pharma underwent a significant restructuring with the Composite Scheme of Arrangement, which led to the demerger of its pharma business from Piramal Enterprises Limited (PEL) and the amalgamation of several subsidiaries into Piramal Pharma. This restructuring was crucial for the company’s growth, enabling it to focus more effectively on its core pharmaceutical business. Following this restructuring, Piramal Pharma was listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE) on October 19, 2022.

The demerger allowed Piramal Pharma to operate as an independent, publicly listed company, and its listing on the stock exchanges provided the company with increased visibility and access to capital markets. This move has also provided investors with the opportunity to invest in Piramal Pharma, and the company’s performance has had a significant impact on Piramal Pharma Share Price, which has garnered the attention of market participants.

Ongoing Expansion and Future Outlook

Piramal Pharma has continued to expand its operations, most notably in the field of antibody drug conjugates (ADCs). The company announced plans to expand its ADC capabilities at its Grangemouth facility in the UK, enhancing its ability to manufacture these complex and highly specialized drugs. The company also focused on expanding its drug substance capabilities at its Riverview facility in the United States, further solidifying its position as a leader in the pharmaceutical manufacturing sector.

The company’s focus on innovation and continued investment in high-growth areas, such as biologics, vaccines, and peptide APIs, has positioned it for sustained growth in the coming years. With its extensive manufacturing capabilities, global reach, and commitment to delivering differentiated products and services, Piramal Pharma is well-positioned to capitalize on the growing demand for innovative pharmaceutical solutions.

Piramal Pharma Limited is a leading player in the global pharmaceutical industry, offering a broad range of products and services across various therapeutic areas. The company’s diverse business segments, strategic partnerships, global manufacturing footprint, and focus on innovation make it a formidable force in the pharmaceutical sector. As Piramal Pharma continues to expand its capabilities and enhance its product offerings, it is poised for continued success in the dynamic and rapidly evolving global pharmaceutical market.